Copper-Associated Hepatopathy in Dogs: Welfare Guide
Disease Overview
Copper-associated hepatopathy (CAH) results from excessive copper accumulation in liver cells, causing oxidative damage, hepatocellular injury, and progressive liver disease. Bedlington Terriers (genetic copper metabolism defect), Labrador Retrievers, Dobermann Pinschers, West Highland White Terriers, and Skye Terriers are predisposed breeds. It can progress from subclinical copper accumulation to chronic active hepatitis, cirrhosis, and liver failure.
Welfare Consequences
Chronic hepatopathy causes progressive welfare harm: hepatic encephalopathy (disorientation, behaviour change, seizures); ascites (abdominal fluid causing distension and discomfort); weight loss; vomiting; and jaundice. Acute haemolytic crisis (copper release from damaged liver causing haemolytic anaemia) causes sudden severe welfare compromise. Liver failure is a prolonged and distressing end-stage condition.
Diagnosis and Screening
Liver biopsy with quantitative copper analysis is the gold standard diagnosis. Routine biochemistry (ALT elevation is often the first indicator) combined with breed predisposition justifies liver biopsy in susceptible breeds showing hepatic enzyme elevations. Genetic testing is available for Bedlington Terrier copper toxicosis (COMMD1 mutation). In predisposed breeds, proactive screening before clinical signs allows early intervention.
Treatment
D-penicillamine (chelating agent) promotes copper excretion and is the mainstay of treatment. Zinc acetate or zinc gluconate reduces intestinal copper absorption and is used for maintenance and prevention. Dietary copper restriction (commercial hepatic diets with reduced copper, avoiding high-copper ingredients like organ meat, shellfish, and some legumes) reduces ongoing copper accumulation. Antioxidant supplementation (SAMe, vitamin E) supports liver function.
Welfare-Centred Breeding Decisions
In Bedlington Terriers, genetic testing allows identification of affected (homozygous), carrier (heterozygous), and clear (normal) individuals. Breeding decisions that avoid producing affected puppies prevent welfare harm in future generations. Breed clubs and breeders working with veterinary genetics to reduce the frequency of causative mutations are making a long-term welfare investment. Regular hepatic enzyme monitoring in predisposed breeds allows early detection and intervention.